Location History:
- Great Neck, NY (US) (2022)
- Rockville, MD (US) (2023)
- Bethesda, MD (US) (2018 - 2024)
Company Filing History:
Years Active: 2018-2024
Title: Innovations of Philip M. Arlen
Introduction
Philip M. Arlen is a notable inventor based in Bethesda, MD, with a significant contribution to the field of biotechnology. He holds a total of six patents, showcasing his innovative approaches to medical treatments and therapies. His work primarily focuses on targeting regulatory T cells (Treg cells) and developing monoclonal antibodies for cancer treatment.
Latest Patents
Arlen's latest patents include groundbreaking methods and compositions for targeting Treg cells. One of his notable inventions, the antibody NEO-201, is designed to bind to Treg cells, facilitating their isolation, detection, and purification. This antibody also has the potential to eliminate Treg cells, which can be crucial in cancer therapies. Another significant patent involves the monoclonal antibody NEO-201, which is highly reactive against various tumor tissues from different carcinomas, including colon, pancreatic, stomach, lung, breast, and uterine cancers. Functional assays have demonstrated that NEO-201 can mediate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells. In vivo studies have shown that NEO-201 preferentially accumulates in tumors while sparing normal organ tissues, indicating its potential for targeted cancer therapy.
Career Highlights
Arlen is currently associated with Precision Biologics, Inc., where he continues to advance his research and development efforts. His innovative work has positioned him as a key figure in the biotechnology sector, particularly in the development of therapeutic antibodies.
Collaborations
Arlen has collaborated with notable colleagues, including Xue-Ping Wang and Kwong Y Tsang, contributing to the advancement of their shared research goals.
Conclusion
Philip M. Arlen's contributions to biotechnology through his patents and innovative research are paving the way for new cancer therapies. His work exemplifies the impact of targeted treatments in improving patient outcomes.